Researchers from the Karolinska Institutet have collaborated with other researchers to develop a compound that prevents inflammation blocking the release of alpha TNF …
A multidisciplinary team of researchers led by Karolinska Institutet in Sweden developed an anti-inflammatory molecule with a new mechanism of action. By inhibiting a certain protein, the researchers were able to reduce signals that cause inflammation. The study was conducted in collaboration with the University of Texas Medical Branch, the University of Uppsala and the University of Stockholm.
"We develop a new pharmacological molecule that inhibits inflammation," says Professor Thomas Helleday of the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who commissioned the study together with Dr. Torkild Visnes and Dr. Armando Cázares-Körner. "It acts on a protein that we believe is a general mechanism of how inflammation in the cells arises."
The discovery is the result of many years of research from the group of Prof. Helleday about how DNA is repaired by the body. One of the objectives was to fight cancer by attacking DNA from tumor cells. Several advances have already been reported, which led, among other things, to a new treatment for breast cancer and congenital cancer using the so-called PARP inhibitors, which has been available for some years.
It was when a new molecule was developed to inhibit the enzyme that repairs oxygen damage to the DNA that the researchers found, to their surprise, that they also dampened inflammation. It has been found that the OGG1 enzyme, in addition to repairing DNA, also causes inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In the trials of mice with acute pulmonary disease, the researchers managed to reduce inflammation.
"This discovery could lead to a new treatment for a very serious state," said Professor Helleday. "Now we will develop our inhibitor of OGG1 and examine whether it can lead to new treatments for inflammatory diseases to cure or alleviate diseases such as sepsis, COPD and severe asthma."
The study was published in the magazine Science